TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 26, 2025, that it has entered...
TYK Medicines
TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 14, 2025, that the results of...
TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis
China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...
TYK Medicines Partners with WuXi STA for Comprehensive CMC Services
Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec...
TYK Medicines Receives CDE Approval for CDK7 Inhibitor TY-2699a Clinical Study
Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug...
TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...
TYK Medicines Secures FDA Approval for Next-Generation TKI Clinical Trial
China-based TYK Medicines, Inc. has announced that it has received clinical trial approval from the...